Familial High Plasminogen Activator Inhibitor with Hypofibrinolysis, a New Pathophysiologic Cause of Osteonecrosis?

C J Glueck; H I Glueck; L Mieczkowski; T Tracy; J Speirs; D Stroop

doi:10.1055/s-0038-1651633

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1993; 69(05): 460-465
DOI: 10.1055/s-0038-1651633

Original Article

Fibrinolysis

Schattauer GmbH Stuttgart

Familial High Plasminogen Activator Inhibitor with Hypofibrinolysis, a New Pathophysiologic Cause of Osteonecrosis?

Autoren

C J Glueck

Cholesterol Center, Jewish Hospital, Ohio, USA
H I Glueck

¹The Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
L Mieczkowski

²Department of Medicine, Kettering Hospital, Kettering Ohio, USA
T Tracy

Cholesterol Center, Jewish Hospital, Ohio, USA
J Speirs

Cholesterol Center, Jewish Hospital, Ohio, USA
D Stroop

¹The Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA

Abstract

als PDF herunterladen

Summary

In a 29 year old white male with osteonecrosis of both hips and a shoulder, and in his family, we measured basal and stimulated (10 min cuff venous occlusion at 100 mgHg) fibrinolytic activity to determine whether low fibrinolytic activity might be heritable and etiologically associated with osteonecrosis. The proband’s basal tPA-Fx was low, 0.08 IU/ml (normal 0.11-1.94), tPA-Ag was normal (11.6 ng/ml), plasminogen activator inhibitor activity (PAI-Fx) was very high, 119 U/ml (normal 3.5-27), as was his plasminogen activator inhibitor antigen (PAI-Ag), 202 ng/ml (normal 3.2-37.1). The proband’s basal PAI-Fx (119) and PAI-Ag (202) were respectively 6 and 13 standard deviations greater than the mean PAI-Fx (17 ± 15 U/ml) and the mean PAI-Ag (25 ± 13 ng/ml) in 172 concomitantly studied hyperlipidemic men. Alpha-2 antiplasmin, fibrinogen, plasminogen and Lp(a) were normal. Despite lowering TG to 301 mg/dl, basal tPA-Fx remained low, 0.05; PAI-Fx and PAI-Ag remained very high (109 and 191). Following venous occlusion, stimulated tPA-Fx remained very low, 0.1 (normal 2.3-11.3), but tPA-Ag rose normally to 17 (normal 8.4-31.4); stimulated PAI-Fx and PAI-Ag were very high, 134 and 223, (normal PAI-Fx 3.6-24, PAI-Ag 12-96). Stimulated D-dimer was < the 10th percentile, 0.084 μg/ml. With such high PAI-Fx available to bind tPA, occlusionstimulated tPA-Fx could not rise, and fibrinolysis could not be initiated. Neither diseases nor drugs could explain the high PAI-Fx and PAI-Ag, low tPA-Fx, or osteonecrosis. The proband’s father, mother, and sister had very high basal PAI-Ag (240, 69, 66 ng/ml), high basal PAI-Fx (24, 24, 35 U/ml), and normal basal tPA-Fx (0.6, 1.0, and 0.2 IU/ml). Basal PAI-Ag, PAI-Fx, and tPA-Fx were normal in the proband’s son (13, 12, 0.3). The proband’s very high PAI-Fx and PAI-Ag appeared to be inherited, possibly as an autosomal dominant trait, producing hypofibrinolysis. We speculate that his osteonecrosis was caused by familial hypofibrinolysis mediated by high PAI, with subsequent inability to activate fibrinolysis, resulting in inadequate lysis of venous thrombi in bone, impaired bone venous circulation, and venous hypertension of bone characteristic of osteonecrosis.

PDF (1515 kb)

Referenzen

References
1 Ichinose A, Espling ES, Takamasu J, Saito H, Shinmyozu K, Maruyama I, Peterson TE, Davie EW. Two types of abnormal genes for plasminogen in families with a predisposition for thrombosis. PNAS 1991; 88: 115-119
2 Ichinose A. Multiple members of the plasminogen-apolipoprotein(a) gene family associated with thrombosis. Biochemistry 1992; 31: 3113-3118
3 Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-350
4 Mannucci PM, Tripodi A. Laboratory screening of inherited thrombotic syndromes. Thromb Haemostas 1987; 57: 247-251
5 Jorgenson M, Bonnevie-Niesen V. Increased concentration of fastacting plasminogen activator in plasma associated with familial venous thrombosis. Br J Haematol 1987; 65: 175-180
6 Patrassi GM, Sartori MT, Saggiorato G, Boeri G, Girolami A. Familial Thrombophilia associated with high levels of plasminogen activator inhibitor. Fibrinolysis 1992; 6: 99-105
7 Nilsson IM, Tengborn L. Impaired fibrinolysis. New evidence in relation to thrombosis. In: 1983 Clinical Aspects of Fibrinlysis and Thrombolysis. Jespersen J, Kluft C, Korsgaard O. (eds). South Jutland University Press; Esbjerg: 1983: 273-291
8 Pizzo SV, Fuchs HE, Doman KA, Petruska DB, Berger H. Release of tissue plasminogen activator and its fast-acting inhibitor in defective fibrinolysis. Arch Intern Med 1986; 146: 188-191
9 Engesser L, Brommer EGP, Kluft C, Briët E. Elevated plasminogen activator inhibitor (PAI), a cause of thrombophilia? A study in 203 patients with familial or sporadic venous thrombophilia. Thromb Haemostas 1989; 62: 673-680
10 Newland JR, Haire WD. Elevated Plasminogen Activator Inhibitor Levels Found in Patients with Malignant Conditions. Am J Clin Pathol 1991; 96: 602-604
11 Glueck CJ, Glueck HI, Tracy T, Speirs J, McCray C, Stroop D. Relationship between Lp(a), lipids, apolipoproteins, and fibrinolytic activity in 191 hyperlipidemic patients. Metabolism 1993; 42: 236-246
12 Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-462
13 Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thrombo-embolic disease. Semin Thromb Hemostas 1990; 26: 207-216
14 Glueck CJ, Glueck HI, Mieczkowski L, Tracy T, Speirs J, Stroop D. Familial hypofibrinolysis with high plasminogen activator activity and antigen and avascular necrosis of the hip. Clin Res 1992; 40 (03) 692 A (Abstract)
15 Mankin JH. Nontraumatic necrosis of bone (osteonecrosis). NEJM 1992; 326: 1473-1479
16 Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements. Clin Lab Med 1989; 9: 105-135
17 Allain C, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470-475
18 McGowan MW, Artiss JD, Strandbergh DR, Zak B. A peroxidasecoupled method for the colorimetric determination of serum triglycerides. Clin Chem 1983; 29: 538-543
19 Assman G, Schriewer H, Schmitz G, Hagele EO. Quantification of high density lipoprotein cholesterol by precipitation with phosphotungstic acid/MgCl₂ . Clin Chem 1983; 29: 2026-2030
20 Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative vitra centrifuge. Clin Chem 1972; 18: 499-502
21 Glueck CJ, McCray C, Speirs J. Measurement of serum Apo A1 and Apo B: comparison of immunoturbidimetric and rate nephelometric techniques. Clin Chim Acta 1991; 197: 123-132
22 Silberman S, Armentrout M, Vella F, Saha A. Macra Lp(a) for quantitation of human lipoprotein (a) by enzymes. Clin Chem 1990; 36 (06) 961. Macra Lp(a) Enzyme Immunoassay Kit.Catalog #D306.Terumo Medical Corp., Elkton, MD 21921.
23 Bergdorf N, Nilsson T, Wallen P. An enzyme linked immunosorbent assay for determination of tissue activator applied to patients with thromboembolic disease. Thromb Haemostas 1983; 50: 740-744
24 Korniger C, Speiser W, Wojta J, Binder BR. Sandwich ELISA for t-PA antigen employing a monoclonal antibody. Thromb Res 1986; 41: 527-535
25 Ranby M, Norman B, Wallen P. A sensitive assay for tissue plasminogen activator. Thromb Res 1982; 27: 743-749
26 Chmielewska J, Wiman B. Determination of tissue plasminogen activator and its fast inhibitor in plasma. Clin Chem 1986; 32: 482-485
27 Eriksson E, Ranby M, Gyzander E, Risberg B. Determination of plasminogen activator inhibitor in plasma using t-PA and a chromogenic single-point poly-D-lysine stimulated assay. Thromb Res 1988; 50: 91-101
28 De Clerk PJ, Verstrecken M, Collen D. Measurement of different forms of plasminogen activator 1 using various monoclonal antibody-based enzyme-linked immunosorbent assays. Fibrinolysis 1990; 4 (Suppl. 02) 132-133
29 Teger-Nilson AC, Friberger P, Gyzander E. Determination of new plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate. Scand J Clin Lab Invest 1977; 37: 403-409
30 Naito K, Aoki N. Assay of alpha₂-plasmin inhibitor activity by means of plasmin specific tripeptide substrate. Thromb Res 1978; 12: 1147-1156
31 Samama M, Schleguel N, Cazenave B, Horellou MM, Conrad J, Castel M, Douenias R. Alpha₂-antiplasmin assay: amidolytic and immunological method. Critical evaluation, results in a clinical material. In: Synthetic Substrates in Clinical Blood Coagulation Assays. Lijnen HR, Collen D, Verstraete M. (eds). Martinus Nijhoff; La Haye: 1980: 93-99
32 Friberger P, Knös M. Plasminogen determination in human plasma. In: Chromogenic Peptide Substrates. Scully MF, Kakkar VV. (eds). Churchill Livingston; Edinburgh: 1979. Chapter 13
33 Friberger P. et al. Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis. 1978 138.
34 Reddy KNN, Markus G. Mechanism of activation of human plasminogen by streptokinase. Presence of active center in streptokinase-plasminogen complex. J Biol Chem 1972; 247: 1683
35 Soria C, Soria J, Samama M. A plasminogen assay using a chromogenic synthetic substrate: results from clinical works and from studies of thrombolysis. In: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Rowan RM, Samama MM, Desnoyers PC. (Eds). Raven Press; New York: 1978. 3: 337-346
36 Miale JB. The fibrometer system of routine coagulation tests. Am J Clin Pathol 1965; 43: 475-480
37 Rylatt DB, Blake AS, Cottis LE. et al. An immunoassay for human Ddimer using monoclonal antibodies. Thromb Res 1983; 31: 767-778
38 Glueck CJ, Glueck HI, Tracy T, Speirs J, Stroop D. Basal and stimulated fibrinolytic activity. Clin Res 1992; 40 (03) 752 A (Abstract)
39 Glueck DJ, Margolin G. Lipoprotein metabolism in the elderly. In: The Merck Manual of Geriatrics. Abrams WG, Berkow RB. (eds). Merck and Co; Rahway, NJ: 1990: 844-873
40 Hekman CM, Loskoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985; 260: 11581-11587
41 Glueck CJ, Freiberg R, Glueck HI, Stroop D, Tracy T. High plasminogen activator inhibitor activity and antigen and hypofibrinolysis, a cause of osteonecrosis?. Clin Res. In press (Abstract)
42 Edelberg JM, Pizzo SV. Lipoprotein (a) inhibits plasminogen activation in a template-dependent manner. Blood Coagulation Fibrinolysis 1991; 2: 759-764
43 Garcia Frade LG, Alvarez JJ, Rayo I. et al. Fibrinolytic parameters and lipoprotein(a) levels in plasma of patients with coronary artery disease. Thromb Res 1991; 63: 407-418
44 Alessi MC, Parra HJ, Joly P. et al. The increased plasma Lp(a) lipoprotein particle concentration in angina pectoris is not associated with hypofibrinolysis. Clin Chim Acta 1990; 188: 119-128
45 Small M, Lowe GDO, MacCuish AC, Forbes DC. The effects of oral stanozolol on fibrinolysis in type 2 diabetes mellitus. Thromb Res 1986; 44: 253-259
46 Kluft C, Preston FE, Malia RG. et al. Stanozolol-induced changes in fibrinolysis and coagulation in healthy adults. Thromb Haemostas 1984; 51: 157-164
47 Gregosiewicz A, Okonski M, Stoecka D. et al. Ischemia of the femoral head in Perthe’s disease: is the cause intra- or extravascular. J Pediatr Orthopedics 1989; 9: 160-162
48 Bick RL. Disorders of Thrombosis and Hemostasis. ASCP Press; Chicago, IL: 1992: 10